A Randomized, Open Label, Multiple Dose, Parallel Group Study to Assess the Safety and Pharmacokinetic Comparability of Two VAY736 Drug Products in Patients With Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Ianalumab (Primary) ; Ianalumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 29 Jan 2019 Planned End Date changed from 2 Sep 2021 to 31 Aug 2021.
- 29 Jan 2019 Planned primary completion date changed from 2 Sep 2021 to 31 Aug 2021.
- 29 Jan 2019 Status changed from not yet recruiting to recruiting.